Wed, Apr 30, 8:16 PM (12 days ago)
**Arcadia Biosciences, Inc. (RKDA) 10-K/A Summary** **Company Overview:** Arcadia Biosciences, Inc. (RKDA) is a publicly traded company listed on the NASDAQ Capital Market. As of March 31, 2025, the company had 1,367,040 shares of common stock outstanding, with an aggregate market value of approximately $4,184,025. **Executive and Board Changes:** - **Thomas J. Schaefer** was appointed as President and Chief Executive Officer in July 2024. - **Mark Kawakami** was appointed as Chief Financial Officer in July 2024. - **Kevin Comcowich** serves as the Chair of the Board of Directors. - The Board of Directors includes **Albert D. Bolles, Ph.D., Lilian Shackelford Murray, Amy Yoder, Deborah Carosella, and Gregory D. Waller**. **Executive Compensation:** - **Thomas J. Schaefer**: Received a total compensation of $499,477 in 2024, including a base salary of $260,000, a bonus of $65,000, and other compensation. - **Mark Kawakami**: Received a total compensation of $370,175 in 2024, including a base salary of $212,742, a bonus of $53,016, and other compensation. - **Stanley E. Jacot, Jr.** (former CEO): Received a severance payment of $288,077 upon resignation. **Director Compensation:** - Directors received cash retainers and meeting attendance fees, with additional fees for committee memberships. - Directors also received stock options, with the number of shares and vesting schedules detailed in the filing. **Related Party Transactions:** - The company has entered into employment agreements with executive officers, including severance and change of control benefits. - The company has also entered into indemnification agreements with non-employee directors. **Audit Committee and Financial Statements:** - The audit committee is comprised of **Mr. Waller, Ms. Shackelford Murray, and Ms. Yoder**. - Deloitte & Touche LLP served as the independent registered public accounting firm, with audit fees totaling $573,555 for 2024. **Future Outlook and Strategic Initiatives:** - The company is focused on strategic initiatives, including a proposed transaction with Roosevelt Resources LP, which involves issuing shares of common stock in exchange for partnership interests. - The company has also entered into various securities purchase agreements and registration rights agreements with institutional and accredited investors. **Risk Factors:** - The company faces risks related to market conditions, regulatory environment, and operational challenges. - The company has implemented policies and procedures to ensure compliance with SEC regulations and to maintain the independence of its audit committee. **Financial Condition:** - The company's financial condition is supported by its equity compensation plans and securities purchase agreements. - The company has maintained three equity compensation plans, with shares remaining available for future issuance. **Market Position:** - The company's market position is influenced by its strategic initiatives and related party transactions. - The company has entered into various securities purchase agreements and registration rights agreements to support its financial condition and market position. **Conclusion:** Arcadia Biosciences, Inc. (RKDA) is focused on strategic initiatives and related party transactions to support its financial condition and market position. The company has implemented policies and procedures to ensure compliance with SEC regulations and to maintain the independence of its audit committee. The company's future outlook is influenced by its strategic initiatives and related party transactions.